The complex interplay between IL-6 and the immune system highlights its context-dependent effects and underscores its potential as both a therapeutic target and biomarker for monitoring the progression of cancer and inflammatory disorders, but it also acts as an immune–inflammatory-related toxicity-predictive biomarker tool in the NGTxC IATA. The gene discussed is IL6; the disease is cancer.